Article info
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
510 SO-C101, a high-affinity IL-15Rbg agonist, induces safe and potent anti-tumor immune activities in patients with solid tumors and supports further clinical investigations
Citation
510 SO-C101, a high-affinity IL-15Rbg agonist, induces safe and potent anti-tumor immune activities in patients with solid tumors and supports further clinical investigations
Publication history
- First published November 10, 2021.
Online issue publication
March 30, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.